Annovis Bio Secures U.S. Patent Through 2044 for Infection-Related Neurological Injuries
Annovis Bio received U.S. Patent No. 12,582,632 B2 covering buntanetap’s use to prevent and treat neurological injuries from viral, bacterial, fungal, protozoan or parasitic brain infections. The patent grants preventive and reversal claims across the full spectrum of implicated pathogens and extends protection through 2044.
1. U.S. Patent No. 12,582,632 B2 Granted
Annovis Bio announced issuance of U.S. Patent No. 12,582,632 B2 covering buntanetap and related compounds for prevention and treatment of neurological injuries caused by brain infections. The patent protection spans administration of these compounds and extends Annovis’s exclusivity until 2044.
2. Broad Spectrum Coverage
The granted patent includes claims for viral, bacterial, fungal, protozoan and parasitic agents implicated in neurodegeneration, reflecting a comprehensive approach to infectious triggers of Alzheimer’s pathology. It covers both prophylactic administration in at-risk healthy individuals and therapeutic use in patients with established neurological damage.
3. Implications for Buntanetap’s Development
Buntanetap’s mechanism of reducing overproduction of amyloid-beta, tau and other aggregating proteins positions it as a candidate to interrupt infection-initiated neurotoxic cascades. This patent strengthens Annovis’s patent estate ahead of its Phase 3 trials in Alzheimer’s and Parkinson’s diseases by protecting an additional therapeutic avenue.